Palvella Therapeutics, Inc.
PVLAHealthcare|Biotechnology|US
$175.92
+19.07 (+12.16%)
DCF Value
$4.71
Tangible Book / Share
$13.62
Cash / Share
$16.29
Clinical Trials (9)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT05643872 A Study Evaluating the Safety and Pharmacokinetics of QTORIN Rapamycin 3.9% Anhydrous Gel in the Treatment of Adults With Pachyonychia Congenita | Pachyonychia Congenita | P3 | Recruiting | 45 | Open-label | PTX-022 |
| NCT06239480 SELVA: A Phase 3 Study Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations | Microcystic Lymphatic Malformation | P3 | Active | 51 | Open-label | QTORIN 3.9% Rapamycin Anhydrous Gel |
| NCT06653842 A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Cutaneous Venous Malformations | Cutaneous Venous Malformations | P2 | Active | 15 | Open-label | QTORIN 3.9% rapamycin anhydrous gel |
| NCT07552077 A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Angiokeratomas (LOTU) | Angiokeratomas | P2 | Recruiting | 15 | Open-label | PTX-022 |
| NCT03920228 Phase 2/3 Study Evaluating the Safety and Efficacy of PTX-022 in Treatment of Adults With Pachyonychia Congenita | Pachyonychia Congenita | P2P3 | Completed | 73 | RCT, Double-blind | PTX-022, Placebo |
| NCT04520750 VALO-2: Study Evaluating the Safety and Efficacy of PTX022 in the Treatment of Adults With Pachyonychia Congenita | Pachyonychia Congenita | P3 | Completed | 36 | Open-label | PTX-022 |
| NCT05180708 A Multicenter, Phase 3 Randomized, Double-Blind, Vehicle-Controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Pachyonychia Congenita | Pachyonychia Congenita | P3 | Completed | 87 | RCT, Double-blind | QTORIN 3.9% rapamycin anhydrous gel, Vehicle |
| NCT04893486 CODY: A Study Evaluating The Safety And Efficacy Of QTORIN 3.9% Sirolimus Topical Gel For The Prevention Of Basal Cell Carcinomas (BCCs) In Patients With Gorlin Syndrome | BCCs in Gorlin Syndrome Patients | P2 | Completed | 73 | RCT, Double-blind | PTX-022, Vehicle comparator |
| NCT05050149 Study Evaluating the Safety and Efficacy of PTX-022 (QTORIN Sirolimus) in the Treatment of Microcystic Lymphatic Malformations | Microcystic Lymphatic Malformation | P2 | Completed | 12 | Open-label | PTX-022 |